^
Association details:
| Biomarker: | FGFR1 rearrangement |
|---|---|
| Cancer: | CNS Tumor |
| Drug: | Lytgobi (futibatinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Futibatinib, an irreversible FGFR1–4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study
Published date:
09/22/2021
Excerpt:
Among the 170 patients who received futibatinib 20 mg QD, 10.6% experienced PRs, and 38.2% experienced SD...FGFR3 mutations (urothelial), and FGFR3 fusions/rearrangements (mostly CNS tumors...FGFR1 fusions/rearrangements (primary CNS and head and neck cancer...also had targetlesion shrinkage...Additionally, PRs were observed in a patient with head and neck cancer harboring an FGFR1-PLAG1 fusion (DOR, 5.6 months) and another patient with an FGFR2 p.Y375C mutation (DOR, 10.3 months) whose primary tumor was unknown.
DOI:
10.1158/2159-8290.CD-21-0697
Trial ID:
